Literature DB >> 28749172

No differences in radiological changes after 3D conformal vs VMAT-based stereotactic radiotherapy for early stage non-small cell lung cancer.

Serena Badellino1, Jacopo Di Muzio1, Giulia Schivazappa2, Alessia Guarneri1, Riccardo Ragona1, Sara Bartoncini1, Elisabetta Trino1, Andrea Riccardo Filippi1, Paolo Fonio2, Umberto Ricardi1.   

Abstract

OBJECTIVE: To compare patterns of acute and late radiological lung injury following either 3D conformal or image-guided volumetric modulated arc therapy stereotactic radiotherapy for Stage I non-small-cell lung cancer.
METHODS: We included 148 patients from a prospective mono-institutional stereotactic body radiation therapy (SBRT) series (time interval 2004-2014), treated with prescription BED10 Gy (at 80%) in the range 100-120 Gy. The first 95 patients (2004-2010) were planned with 3D-CRT, with a stereotactic body frame. The second cohort (2010-2014) included 53 patients, planned with volumetric IMRT on a smaller planning target volume generated from a patient's specific internal target volume, with a frameless approach through cone-beam CT guidance. Acute and late radiological modifications were scored based on modified Kimura's and Koenig's classifications, respectively.
RESULTS: Median follow-up time was 20.5 months. The incidence of acute radiological changes was superimposable between the groups: increased density was observed in 68.4 and 64.2% of patients for 3D-CRT and VMAT, respectively, and patchy ground glass opacity in 23.7 and 24.5%, respectively; diffuse ground glass opacity was 2.6 vs 9.4%, respectively, and patchy consolidation 2.6 vs 1.9%, respectively. Late changes occurred in approximately 60% of patients: modified conventional pattern was the most frequent modification (25 vs 32.6%, respectively); other patterns were less common (mass-like 19.6 vs 17.4%, and scar-like 13 vs 10.9%, respectively).
CONCLUSION: Results of the present study indicate that the pattern of radiological lung changes following SBRT for peripheral early stage non-small-cell lung cancer is not influenced by the different techniques used for planning and delivery. Advances in knowledge: This comparative observational study shows that smaller margins, image guidance and most importantly dose distribution do not change the pattern of radiological injury after lung SBRT; the same scoring system can be used, and expected incidence is similar.

Entities:  

Mesh:

Year:  2017        PMID: 28749172      PMCID: PMC5853362          DOI: 10.1259/bjr.20170143

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  19 in total

1.  Tomotherapy.

Authors:  T R Mackie; J Balog; K Ruchala; D Shepard; S Aldridge; E Fitchard; P Reckwerdt; G Olivera; T McNutt; M Mehta
Journal:  Semin Radiat Oncol       Date:  1999-01       Impact factor: 5.934

2.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

3.  Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques.

Authors:  David A Palma; Suresh Senan; Cornelis J A Haasbeek; Wilko F A R Verbakel; Andrew Vincent; Frank Lagerwaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-26       Impact factor: 7.038

4.  Stereotactic Ablative Radiotherapy for stage I histologically proven non-small cell lung cancer: an Italian multicenter observational study.

Authors:  Umberto Ricardi; Giovanni Frezza; Andrea Riccardo Filippi; Serena Badellino; Mario Levis; Piera Navarria; Fabrizio Salvi; Michela Marcenaro; Marco Trovò; Alessia Guarneri; Renzo Corvò; Marta Scorsetti
Journal:  Lung Cancer       Date:  2014-03-13       Impact factor: 5.705

5.  Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer.

Authors:  Tingyi Xia; Hongqi Li; Qingxuan Sun; Yingjie Wang; Naibin Fan; Yong Yu; Ping Li; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-06-09       Impact factor: 7.038

6.  Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC.

Authors:  S Arcangeli; L Agolli; L Portalone; M R Migliorino; M G Lopergolo; A Monaco; J Dognini; M C Pressello; S Bracci; V Donato
Journal:  Br J Radiol       Date:  2015-02-03       Impact factor: 3.039

7.  2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up.

Authors:  J Vansteenkiste; L Crinò; C Dooms; J Y Douillard; C Faivre-Finn; E Lim; G Rocco; S Senan; P Van Schil; G Veronesi; R Stahel; S Peters; E Felip
Journal:  Ann Oncol       Date:  2014-02-20       Impact factor: 32.976

8.  Radiation injury of the lung after three-dimensional conformal radiation therapy.

Authors:  Titus R Koenig; Reginald F Munden; Jeremy J Erasmus; Bradley S Sabloff; Gregory W Gladish; Ritsuko Komaki; Craig W Stevens
Journal:  AJR Am J Roentgenol       Date:  2002-06       Impact factor: 3.959

9.  CT appearance of radiation injury of the lung and clinical symptoms after stereotactic body radiation therapy (SBRT) for lung cancers: are patients with pulmonary emphysema also candidates for SBRT for lung cancers?

Authors:  Tomoki Kimura; Kanji Matsuura; Yuji Murakami; Yasutoshi Hashimoto; Masahiro Kenjo; Yuko Kaneyasu; Koichi Wadasaki; Yutaka Hirokawa; Katsuhide Ito; Motoomi Okawa
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-08-14       Impact factor: 7.038

10.  Late radiologic changes after stereotactic ablative radiotherapy for early stage lung cancer: a comparison of fixed-beam versus arc delivery techniques.

Authors:  Sashendra Senthi; Max Dahele; Peter M van de Ven; Ben J Slotman; Suresh Senan
Journal:  Radiother Oncol       Date:  2013-09-20       Impact factor: 6.280

View more
  5 in total

1.  Impact of tumor size and location on lung dose difference between stereotactic body radiation therapy techniques for non-small cell lung cancer.

Authors:  Seong Soon Jang; Yohan Shin; Suk Young Park; Gil Ja Huh; Young Jun Yang
Journal:  Thorac Cancer       Date:  2021-10-24       Impact factor: 3.500

2.  A case report of long-term successful stereotactic arrhythmia radioablation in a cardiac contractility modulation device carrier with giant left atrium, including a detailed dosimetric analysis.

Authors:  Mario Levis; Veronica Dusi; Massimo Magnano; Marzia Cerrato; Elena Gallio; Alessandro Depaoli; Federico Ferraris; Gaetano Maria De Ferrari; Umberto Ricardi; Matteo Anselmino
Journal:  Front Cardiovasc Med       Date:  2022-08-22

3.  Dosimetric Evaluation of Simplified Knowledge-Based Plan with an Extensive Stepping Validation Approach in Volumetric-Modulated Arc Therapy-Stereotactic Body Radiotherapy for Lung Cancer.

Authors:  Yutaro Wada; Hajime Monzen; Mikoto Tamura; Masakazu Otsuka; Masahiro Inada; Kazuki Ishikawa; Hiroshi Doi; Kiyoshi Nakamatsu; Yasumasa Nishimura
Journal:  J Med Phys       Date:  2021-05-05

4.  Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer.

Authors:  Michael Mix; Sean Tanny; Tamara Nsouli; Ryan Alden; Rishabh Chaudhari; Russell Kincaid; Paula F Rosenbaum; Jeffrey A Bogart; Paul Aridgides
Journal:  Lung Cancer (Auckl)       Date:  2019-12-20

5.  Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC.

Authors:  Serena Badellino; Mario Levis; Erica Maria Cuffini; Marzia Cerrato; Erika Orlandi; Ilaria Chiovatero; Arianna Aprile; Alessio Gastino; Chiara Cavallin; Giuseppe Carlo Iorio; Ramona Parise; Cristina Mantovani; Umberto Ricardi
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.